September 20, 2017 07:16 AM EDT
R&D

Al­ny­lam achieves break­through RNAi suc­cess as PhI­II patisir­an study hits all goals, shares soar

John Carroll

Editor & Founder

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: A puz­zling up­date from No­vo Nordisk and new da­ta from Roche at #ADA25

FDA's top cell and gene ther­a­py lead­ers ex­it agency in on­go­ing CBER changes

Com­pass claims Phase 3 win in de­pres­sion for psilo­cy­bin drug, moves clos­er to FDA fil­ing

Ver­tex's di­a­betes cell ther­a­py al­lows 10 pa­tients to come off in­sulin

Il­lu­mi­na to buy So­ma­Log­ic for $350M, push­ing fur­ther in­to pro­teomics

sponsored

Dig­i­tal Twins in GMP Man­u­fac­tur­ing: Shap­ing the Fu­ture of CPV with Aizon

A service from the Financial Times